The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:
* Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population?
Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health.
Participants will:
* Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.
Emiratis residing in Abu Dhabi emirate
Aged 25-50 years
BMI 30-35 kg/m²
Thiqa cardholder
Aged under 25 years or over 50 years of age
BMI range under 30 kg/m2 and over 35 kg/m2
Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)
Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)
Institute for Healthier Living Abu Dhabi
Lead sponsor
Abu Dhabi Public Health Centre
Collaborator